Etoricoxib tolerability in patients with hypersensitivity to nonsteroidal anti-inflammatory drugs

Marinella Viola, Donato Quaratino, Francesco Gaeta, Cristiano Caruso, Rocco Valluzzi, Antonino Romano

Research output: Contribution to journalArticlepeer-review


Background: Adverse reactions to nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly observed, particularly among patients with chronic urticaria or asthma. The identification of a safe and reliable alternative is a frequent problem in clinical practice. Our aim was to investigate the clinical tolerability of etoricoxib, a new selective cyclooxygenase-2 inhibitor, in a group of patients with well-established NSAID hypersensitivity. Methods: We assessed 31 adults (21 women and 10 men) who reported one or more adverse reactions to NSAIDs, manifested as cutaneous, respiratory or anaphylactic symptoms. Sixteen of them reported reactions to a single NSAID (single reactors) and 15 to more than one NSAID (multiple reactors); the most frequently involved drug was acetylsalicylic acid. First, each patient underwent allergologic tests (skin and/or oral challenge tests) with culprit NSAIDs and then tolerability tests with increasing doses of etoricoxib up to 120 mg. All challenges were performed under single-blind, placebo-controlled conditions. Results: NSAID hypersensitivity was diagnosed in all 31 patients: 3 displayed positive results to pyrazolone skin tests and the other 28 to challenges with culprit NSAIDs. None reacted to either placebos or etoricoxib. Conclusions: Etoricoxib seems to be a safe alternative for patients with well-demonstrated NSAID hypersensitivity.

Original languageEnglish
Pages (from-to)103-108
Number of pages6
JournalInternational Archives of Allergy and Immunology
Issue number2
Publication statusPublished - May 2007


  • Etoricoxib
  • Hypersensitivity
  • Nonsteroidal anti-inflammatory drugs
  • Oral challenge test
  • Pyrazolones
  • Skin test

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy


Dive into the research topics of 'Etoricoxib tolerability in patients with hypersensitivity to nonsteroidal anti-inflammatory drugs'. Together they form a unique fingerprint.

Cite this